Generalized Anxiety Disorder

Complex MONDO:0001942 Pathograph 5 Show in embeddings browser Psychiatric Disease

Generalized anxiety disorder (GAD) is a chronic psychiatric disorder characterized by excessive, difficult-to-control worry about multiple domains, accompanied by restlessness, fatigue, irritability, muscle tension, and sleep disturbance. Its pathophysiology involves amygdala hyperactivity with impaired prefrontal regulation, GABAergic and serotonergic system dysfunction, hypothalamic-pituitary-adrenal axis dysregulation, and noradrenergic hyperactivity.

Ask OpenScientist

Ask a research question about Generalized Anxiety Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
7
Phenotypes
1
Gaps
5
Pathograph
4
Genes
8
Medical Actions
1
Datasets
3
Models
10
References
2
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC
?

Discussions and Knowledge Gaps

1
Do zebrafish anxiolytic assays report the human GAD treatment hierarchy, given that acute SSRI exposure and the GABA-A agonist chlordiazepoxide both fail to produce anxiolysis in them while buspirone and diazepam succeed?
HUMAN MODEL MISMATCH OPEN gad_zebrafish_anxiolytic_class_mismatch
Attached to
pathophysiology#Serotonin Dysregulation pathophysiology#GABA System Dysfunction
Across the three zebrafish assays curated here the pharmacological pattern does not match human GAD practice. SSRIs are first-line in humans, yet acute fluoxetine leaves larval edge preference unchanged; chlordiazepoxide is an effective GABA-A agonist and is anxiolytic in rodents, yet produces sedation without anxiolysis in the adult novel-tank assay; while buspirone and diazepam are active in both. Two explanations are compatible with the data and are not distinguished by it - an exposure-duration artefact (acute immersion cannot express the weeks-long adaptation human SSRI anxiolysis requires) or genuine divergence in receptor-level pharmacology between teleost and mammalian anxiety circuits. Which it is determines whether these assays may be used to screen serotonergic anxiolytics at all, so it should be resolved rather than left implicit in the per-model limitations.
Proposed experiments
Sub-chronic versus acute SSRI exposure in larval and adult zebrafish anxiety assays
gad_zebrafish_chronic_ssri_exposure
Run matched dose-response curves for fluoxetine under acute immersion and under multi-day waterborne exposure in both the larval edge-preference and adult novel-tank assays, with diazepam and buspirone as in-assay positive controls and swim speed as a sedation control throughout.
Decision criterion
Whether anxiolysis appears under sub-chronic but not acute exposure, at doses that leave locomotion intact.
Supporting outcome
  • Anxiolysis emerging only after sustained exposure would show the null is an exposure-duration artefact, leaving the assays usable for serotonergic screening provided the dosing schedule is matched to the human one.
Refuting outcome
  • A persistent null under sustained exposure at non-sedative doses would indicate genuine divergence in serotonergic anxiolytic pharmacology and argue against using these assays to screen reuptake inhibitors.
Raised while adding structured animal-model links for issue #4873; the underlying results were already cited on the GABA and serotonin nodes but the conflict between them had not been recorded anywhere.
⚙

Pathophysiology

7
Amygdala Hyperactivity
Exaggerated amygdala response to perceived threats leads to excessive fear and anxiety. Reduced prefrontal cortex regulation of amygdala activity.
Amygdala Pyramidal Neuron CL:4023110 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Amygdala Pyramidal Neuron (CL:4023110). CL:4023110 is a cell type from the Cell Ontology.
Fear Response GO:0042596 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Fear Response (GO:0042596). GO:0042596 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:38865810 SUPPORT
"Evidence indicates that anxiety disorders arise from an imbalance in the functioning of brain circuits that govern the modulation of emotional responses to possibly threatening stimuli. The circuits under consideration in this context include the amygdala's bottom-up activity, which signifies..."
This evidence supports the model of amygdala hyperactivity in anxiety and the role of prefrontal cortex in regulating amygdala responses to threat stimuli.
GABA System Dysfunction
Reduced GABAergic inhibition contributes to neuronal hyperexcitability and anxiety. Benzodiazepines enhance GABA function.
GABAergic Interneuron CL:0011005 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic Interneuron (CL:0011005). CL:0011005 is a cell type from the Cell Ontology.
GABAergic Transmission GO:0051932 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves GABAergic Transmission, annotated with synaptic transmission, GABAergic (GO:0051932). GO:0051932 is a biological process from the Gene Ontology.
Animal models
Adult zebrafish novel tank diving anxiolytic-screening assay Zebrafish (Danio rerio) perturbs The benzodiazepine diazepam reduces the diving response at non-sedative doses, indicating that benzodiazepine-GABA-A signalling is present and anxiolytically effective in zebrafish. The second benzodiazepine tested, chlordiazepoxide, produced sedation but no anxiolysis, so the model engages this node only partially.
Larval zebrafish dark-flash thigmotaxis assay Zebrafish (Danio rerio) perturbs Diazepam attenuates dark-flash-evoked thigmotaxis in larvae, and the anxiogenic reference compound caffeine enhances it, giving the assay bidirectional pharmacological validation of the benzodiazepine-GABA-A anxiolytic target at larval stages.
Larval zebrafish edge-preference (thigmotaxis) assay Zebrafish (Danio rerio) perturbs Diazepam reduces larval edge preference with or without visual stimuli, independently reproducing the benzodiazepine sensitivity seen in the dark-flash thigmotaxis and adult novel-tank assays.
Show evidence (4 references)
PMID:38865810 SUPPORT
"A decrease in GABAergic activity is present in both anxiety disorders and severe depression. Research on cerebral functional imaging in depressive individuals has shown reduced levels of GABA within the cortical regions. Additionally, animal studies demonstrated that a reduction in the..."
This evidence demonstrates reduced GABAergic activity in anxiety disorders through both imaging studies and animal models showing that decreased GABA receptor expression leads to anxiety-like behavior.
PMID:38865810 SUPPORT
"The amygdala consists of inhibitory networks composed of GABAergic interneurons, responsible for modulating anxiety responses in both normal and pathological conditions. The GABAA receptor has allosteric sites (e.g., α/γ, γ/β, and α/β) which enable regulation of neuronal inhibition in the..."
This supports the mechanism of GABAergic dysfunction in the amygdala and explains how benzodiazepines work by targeting GABAA receptor allosteric sites to enhance inhibition.
PMID:39294497 NO_EVIDENCE
"We leveraged information from more than 1.2 million participants, including 97,383 cases, to investigate the genetics of anxiety disorders across five continental groups. Through ancestry-specific and cross-ancestry genome-wide association studies, we identified 51 anxiety-associated loci, 39 of..."
This snippet supports broad genetic architecture of anxiety disorders but does not directly provide evidence for GABA system dysfunction.
+ 1 more reference
Serotonin Dysregulation
Altered serotonin signaling, particularly in raphe-prefrontal circuits, contributes to anxiety. SSRIs are first-line treatment.
Serotonergic Neuron CL:0000850 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Serotonergic Neuron (CL:0000850). CL:0000850 is a cell type from the Cell Ontology.
Serotonin Signaling GO:0007268 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Serotonin Signaling, annotated with chemical synaptic transmission (GO:0007268). GO:0007268 is a biological process from the Gene Ontology.
Animal models
Adult zebrafish novel tank diving anxiolytic-screening assay Zebrafish (Danio rerio) perturbs Acute immersion in the 5-HT1A receptor agonist buspirone reduces the diving response at doses that do not slow swimming, showing that the serotonergic (5-HT1A) anxiolytic target underlying this node is functionally conserved and pharmacologically addressable in zebrafish.
Larval zebrafish edge-preference (thigmotaxis) assay Zebrafish (Danio rerio) fails to recapitulate Acute fluoxetine, a selective serotonin reuptake inhibitor and the drug class that is first-line for human GAD, did not alter larval edge preference, while diazepam tested in the same assay did. The assay therefore does not reproduce the serotonergic arm of human GAD pharmacology.
Show evidence (3 references)
PMID:24936175 SUPPORT
"Decreased serotonergic activity has been implicated in anxiety and major depression, and antidepressants directly or indirectly increase the long-term activity of the serotonin system. A key component of serotonin circuitry is the 5-HT1A autoreceptor, which functions as the major somatodendritic..."
This evidence establishes the role of decreased serotonergic activity in anxiety and explains how antidepressants work by increasing serotonin system activity.
PMID:24936175 SUPPORT
"In addition, 5-HT1A heteroreceptors are abundantly expressed post-synaptically in the prefrontal cortex (PFC), amygdala, and hippocampus to mediate serotonin actions on fear, anxiety, stress, and cognition."
This supports the specific role of serotonin signaling in prefrontal-limbic circuits that regulate anxiety and fear responses.
PMID:19643124 SUPPORT Model Organism
"Buspirone, a serotonergic (5HT(1A) receptor agonist) anxiolytic drug with some D(2) dopaminergic effect, had a pronounced anxiolytic-like effect in the zebrafish diving model at doses that did not have sedative effects."
New Approach Methodology (NAM) evidence — in the zebrafish novel-tank diving assay, the 5-HT1A receptor agonist buspirone produces a pronounced anxiolytic-like effect at non-sedative doses, supporting functional conservation of serotonergic (5-HT1A) anxiolytic signaling and the utility of this animal-model alternative for screening serotonergic anxiolytics relevant to GAD.
HPA Axis Dysregulation
Chronic activation of the stress response system with elevated cortisol contributes to sustained anxiety and physical symptoms.
Stress Response GO:0006950 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Stress Response, annotated with response to stress (GO:0006950). GO:0006950 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:20808146 SUPPORT
"Generalized anxiety disorder (GAD) is a common disorder in older adults, which has been linked to hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in this age group."
This evidence directly links GAD to HPA axis hyperactivity, particularly in older adults.
PMID:20808146 SUPPORT
"Compared with placebo-treated patients, SSRI-treated patients had a significantly greater reduction in both peak and total cortisol. This reduction in cortisol was limited to patients with elevated (above the median) baseline cortisol, in whom SSRI-treated patients showed substantially greater..."
This demonstrates that HPA axis hyperactivity with elevated cortisol is present in GAD patients and that successful treatment reduces cortisol levels in parallel with anxiety symptom reduction.
Noradrenergic Hyperactivity
Elevated norepinephrine activity in locus coeruleus contributes to hyperarousal and somatic symptoms of anxiety.
Noradrenergic Neuron CL:0008025 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Noradrenergic Neuron (CL:0008025). CL:0008025 is a cell type from the Cell Ontology.
Oxidative Stress
Increased oxidative stress markers and reduced antioxidant enzyme activity in GAD patients. Elevated malondialdehyde and reduced superoxide dismutase correlate with symptom severity.
Show evidence (2 references)
PMID:38204917 SUPPORT
"The 8-OHdG values of the GAD group were determined to be statistically significantly higher than those of the control group (p=0.028)."
This demonstrates elevated oxidative DNA damage in GAD patients as measured by 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative stress.
PMID:38204917 SUPPORT
"The results of this study showed that there could be DNA damage because of oxidative stress in GAD patients."
This concludes that oxidative stress contributes to the pathophysiology of GAD through DNA damage mechanisms.
Epigenetic Alterations
DNA methylation changes in anxiety-related genes, particularly in monocytes and granulocytes. Methylation sites identified in genes involved in neurogenesis and fear memory.
Monocyte CL:0000576 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Monocyte (CL:0000576). CL:0000576 is a cell type from the Cell Ontology. Granulocyte CL:0000094 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Granulocyte (CL:0000094). CL:0000094 is a cell type from the Cell Ontology.
Show evidence (2 references)
PMID:37542162 SUPPORT
"Applying an enrichment-based sequencing approach covering nearly 28 million autosomal CpG sites, we conducted a methylome-wide association study (MWAS) of lifetime ANX in 1132 participants (618 cases/514 controls) from the Netherlands Study of Depression and Anxiety. Using epigenomic..."
This large-scale epigenome-wide study identifies hundreds of significant DNA methylation sites associated with anxiety disorders, supporting the role of epigenetic mechanisms in GAD pathophysiology.
PMID:37542162 SUPPORT
"In monocytes, two specific sites in the FZR1 gene showed significant replication after Bonferroni correction with an additional 15 nominally replicated sites in monocytes and 4 in T-cells. FZR1 regulates neurogenesis in the hippocampus, and its knockout leads to impairments in associative fear..."
This identifies FZR1 as a key gene with replicable methylation changes in anxiety, linking epigenetic alterations to hippocampal neurogenesis and fear memory mechanisms.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Generalized Anxiety Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Musculoskeletal 1
Muscle Tension FREQUENT Muscle stiffness HP:0003552 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Muscle Tension, annotated with Muscle stiffness (HP:0003552). HP:0003552 is a phenotype from the Human Phenotype Ontology.
Nervous System 4
Excessive Worry VERY_FREQUENT Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Persistent, difficult to control
Show evidence (1 reference)
PMID:39294497 NO_EVIDENCE
"The heritability of anxiety was enriched for genes expressed in the limbic system, cerebral cortex, cerebellum, metencephalon, entorhinal cortex and brain stem."
This snippet supports genetic architecture of anxiety disorders but does not directly evidence the specific clinical phenotype of excessive worry.
Restlessness VERY_FREQUENT HP:0000711 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Restlessness (HP:0000711). HP:0000711 is a phenotype from the Human Phenotype Ontology.
Sleep Disturbance FREQUENT HP:0002360 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insomnia, annotated with Sleep disturbance (HP:0002360). HP:0002360 is a phenotype from the Human Phenotype Ontology.
Difficulty falling or staying asleep
Irritability FREQUENT HP:0000737 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Irritability (HP:0000737). HP:0000737 is a phenotype from the Human Phenotype Ontology.
Constitutional 1
Fatigue FREQUENT HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Other 1
Difficulty Concentrating FREQUENT Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Poor Concentration, annotated with Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology.
🧬

Genetic Associations

4
SLC6A4 (Risk Factor)
Gene: SLC6A4 hgnc:11050 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SLC6A4 (hgnc:11050). hgnc:11050 is a gene from the HUGO Gene Nomenclature Committee.
COMT (Risk Factor)
Gene: COMT hgnc:2228 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is COMT (hgnc:2228). hgnc:2228 is a gene from the HUGO Gene Nomenclature Committee.
CRHR1 (Risk Factor)
Gene: CRHR1 hgnc:2357 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CRHR1 (hgnc:2357). hgnc:2357 is a gene from the HUGO Gene Nomenclature Committee.
NPY (Risk Factor)
Gene: NPY hgnc:7955 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NPY (hgnc:7955). hgnc:7955 is a gene from the HUGO Gene Nomenclature Committee.
💊

Medical Actions

8
SSRIs
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: escitalopram CHEBI:36791 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses escitalopram (CHEBI:36791). CHEBI:36791 is a therapeutic agent from Chemical Entities of Biological Interest.
First-line pharmacotherapy (escitalopram, sertraline, paroxetine).
SNRIs
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: venlafaxine CHEBI:9943 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses venlafaxine (CHEBI:9943). CHEBI:9943 is a therapeutic agent from Chemical Entities of Biological Interest.
Alternative first-line (venlafaxine, duloxetine).
Buspirone
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: buspirone CHEBI:3223 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses buspirone (CHEBI:3223). CHEBI:3223 is a therapeutic agent from Chemical Entities of Biological Interest.
Non-benzodiazepine anxiolytic, no dependence risk.
Benzodiazepines
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: benzodiazepine NCIT:C1012 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses benzodiazepine (NCIT:C1012). NCIT:C1012 is a therapeutic agent from the NCI Thesaurus.
Short-term use for severe symptoms, dependence risk.
Pregabalin
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: pregabalin CHEBI:64356 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses pregabalin (CHEBI:64356). CHEBI:64356 is a therapeutic agent from Chemical Entities of Biological Interest.
Effective in GAD, approved in Europe.
Cognitive Behavioral Therapy
Action: Cognitive Behavior TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Cognitive Behavior Therapy (NCIT:C64345). NCIT:C64345 is a clinical intervention from the NCI Thesaurus. NCIT:C64345
First-line psychotherapy, addresses worry and avoidance.
Relaxation Training
Action: Relaxation TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Relaxation Therapy (NCIT:C15316). NCIT:C15316 is a clinical intervention from the NCI Thesaurus. NCIT:C15316
Progressive muscle relaxation, breathing exercises.
Mindfulness-Based Therapy
Action: Mindfulness RelaxationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Mindfulness Relaxation (NCIT:C93327). NCIT:C93327 is a clinical intervention from the NCI Thesaurus. NCIT:C93327
Reduces worry and rumination.
🌍

Environmental Factors

4
Childhood Adversity
psychological stress XCO:0001265 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is psychological stress, annotated with stress (XCO:0001265). XCO:0001265 is an exposure from the Experimental Conditions Ontology.
Major risk factor
Show evidence (1 reference)
PMID:25089514 SUPPORT Human Clinical
"GAD was associated with stressful life events in childhood and adulthood, and personality"
Systematic review of cohort studies finds childhood stressful life events among the psychosocial risk factors for GAD onset.
Chronic Stress
psychological stress XCO:0001265 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is psychological stress, annotated with stress (XCO:0001265). XCO:0001265 is an exposure from the Experimental Conditions Ontology.
Precipitates and maintains
Show evidence (1 reference)
PMID:29503978 SUPPORT Human Clinical
"Increased cumulative effects of stress on the human body (allostatic load) are linked to many adverse health consequences, including psychiatric illnesses such as GAD"
Review of GAD neurobiology links the cumulative burden of chronic stress (allostatic load) specifically to GAD, supporting chronic stress as a precipitating exposure for this disease.
Trauma
Can trigger onset
Show evidence (1 reference)
PMID:9166642 SUPPORT Human Clinical
"GAD individuals were found to be more likely than nonanxious controls to report exposure to a potentially traumatizing event"
Study finds GAD patients report greater prior exposure to potentially traumatizing events than nonanxious controls.
Caffeine
caffeine exposure ECTO:9000205 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is caffeine exposure, annotated with exposure to caffeine (ECTO:9000205). ECTO:9000205 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Can exacerbate symptoms
Show evidence (1 reference)
PMID:1444724 SUPPORT Human Clinical
"patients with GAD are abnormally sensitive to caffeine"
Controlled trial finds GAD patients show abnormal anxiogenic sensitivity to oral caffeine compared to normal subjects.
🔬

Biochemical Markers

2
Cortisol (Elevated)
Context: Chronic stress activation
GABA (Decreased)
Context: Reduced inhibitory tone
📊

Related Datasets

1
Blood gene expression profiles associated with symptoms of generalized anxiety disorder geo:GSE61672
Prospective epidemiological studies found that generalized anxiety disorder (GAD) can impair immune function and increase risk for cardiovascular disease or events. Mechanisms underlying the physiological reververations of anxiety, however, are still elusive. Hence, we aimed to investigate molecular processes mediating effects of anxiety on physical health using blood gene expression profiles of 546 community participants. Of these, 179 met the status of controls and 157 cases of anxiety.
human MICROARRAY n=546
PMID:25300922
Identified by GEO DataSets index search for Generalized Anxiety Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
🐁

Animal Models

3
Adult zebrafish novel tank diving anxiolytic-screening assay
Adult zebrafish placed in a novel tank initially dwell in the bottom third and progressively explore higher levels of the tank. The proportion of time spent bottom-dwelling serves as the anxiety index, while swim speed is recorded in parallel so that sedation can be separated from anxiolysis. Drugs are given by brief immersion rather than injection. As a New Approach Methodology-tier behavioural pharmacology screen the assay is inexpensive and higher-throughput than its rodent equivalents, and it discriminates anxiolytic drugs across serotonergic, benzodiazepine and nicotinic classes.
Anxiety-like bottom dwelling (diving response) in a novel environment
Species
Zebrafish (Danio rerio)
Genotype
Wild type (pharmacological assay; no engineered allele)
Publication
PMID:19643124
Pathograph links
Serotonin Dysregulation perturbs fidelity: moderate Acute immersion in the 5-HT1A receptor agonist buspirone reduces the diving response at doses that do not slow swimming, showing that the serotonergic (5-HT1A) anxiolytic target underlying this node is functionally conserved and pharmacologically addressable in zebrafish.
Limitations: Buspirone also carries D2 dopaminergic activity, so the effect cannot be attributed to 5-HT1A signalling alone, and a single 3-minute immersion cannot model the weeks of treatment that human serotonergic anxiolysis requires. The assay demonstrates conservation of an anxiolytic drug target, not that zebrafish reproduce the raphe-prefrontal serotonergic pathology curated for human GAD.
Readouts
Novel-tank bottom dwelling under buspirone
Time spent in the bottom third of the novel tank across a 5-minute session after brief buspirone immersion, compared with vehicle controls, with swim speed measured concurrently as a sedation control.
Direction: DECREASED
Interpretation: A fall in bottom dwelling with no concurrent fall in swim speed is read as anxiolysis rather than sedation, so the readout reports specifically on pharmacological engagement of the serotonergic arm.
Show evidence (1 reference)
PMID:19643124 SUPPORT Model Organism
"Buspirone, a serotonergic (5HT(1A) receptor agonist) anxiolytic drug with some D(2) dopaminergic effect, had a pronounced anxiolytic-like effect in the zebrafish diving model at doses that did not have sedative effects."
Reports the dose-controlled behavioural measurement behind this readout, including the explicit absence of sedation at the effective doses.
Show evidence (1 reference)
PMID:19643124 SUPPORT Model Organism
"The zebrafish novel tank diving task can be useful in discriminating anxiolytic drugs of several classes (serotonergic, benzodiazepines and nicotinic)."
Supports treating this assay as informative for the serotonergic arm of GAD pharmacology, since the authors' stated claim is class-level discrimination that includes serotonergic anxiolytics.
GABA System Dysfunction perturbs fidelity: moderate The benzodiazepine diazepam reduces the diving response at non-sedative doses, indicating that benzodiazepine-GABA-A signalling is present and anxiolytically effective in zebrafish. The second benzodiazepine tested, chlordiazepoxide, produced sedation but no anxiolysis, so the model engages this node only partially.
Limitations: Chlordiazepoxide is an effective GABA-A agonist and is anxiolytic in rodents, yet produced no reduction in bottom dwelling here over a broad dose range; the diazepam dose-response was also biphasic. Benzodiazepine responsiveness is therefore compound-specific in this model, and a negative result for a GABAergic compound must not be transferred to human GAD as evidence against a GABAergic mechanism.
Readouts
Novel-tank bottom dwelling under diazepam
Time spent in the bottom third of the novel tank after brief diazepam immersion, compared with vehicle controls, with swim speed measured concurrently as a sedation control.
Direction: DECREASED
Interpretation: Anxiolysis at doses that leave swimming intact is the positive readout for functional benzodiazepine-GABA-A signalling in this model.
Show evidence (1 reference)
PMID:19643124 SUPPORT Model Organism
"Diazepam another benzodiazepine anxiolytic drug did produce an anxiolytic effect at doses that did not cause sedation."
Reports the measurement behind this readout, with sedation explicitly excluded as the explanation.
Novel-tank bottom dwelling under chlordiazepoxide
The same bottom-dwelling measure after chlordiazepoxide immersion across a dose range extending up to sedative concentrations.
Direction: UNCHANGED
Interpretation: A genuine negative result: the compound reached behaviourally active concentrations (it caused sedation) without producing anxiolysis, so the null is not explained by failure to reach the target tissue. This bounds how far benzodiazepine pharmacology in this model may be generalized.
Show evidence (1 reference)
PMID:19643124 SUPPORT Model Organism
"In contrast, chlordiazepoxide, a benzodiazepine anxiolytic drug, which is an effective agonist at GABA-A receptors, did not produce signs of anxiolysis in zebrafish over a broad dose range up to those that caused sedation."
Documents the negative readout and confirms the compound was behaviourally active at the doses tested.
Show evidence (1 reference)
PMID:19643124 SUPPORT Model Organism
"The zebrafish novel tank diving task can be useful in discriminating anxiolytic drugs of several classes (serotonergic, benzodiazepines and nicotinic)."
Supports the assay as informative for benzodiazepine-GABA-A pharmacology, but only partially, because one of the two benzodiazepines tested failed to produce anxiolysis.
Scope is limited to the two neurotransmitter mechanisms the publication actually manipulated. The model is deliberately not linked to Amygdala Hyperactivity, HPA Axis Dysregulation, or the disease-level phenotypes, because no neural, endocrine, or symptom-level measurement was made.
Larval zebrafish dark-flash thigmotaxis assay
Thigmotaxis ("wall-hugging") in 5-days-post-fertilization larvae, triggered by a sudden light-to-darkness transition and scored in a standard 24-well plate over a 10-minute session. This is the larval, plate-based tier of zebrafish anxiety modelling and the closest zebrafish analogue of a New Approach Methodology: it runs at medium-to-high throughput on early-stage larvae and reads out with both anxiolytic and anxiogenic reference compounds.
Anxiety-like thigmotaxis (wall-hugging) after a sudden light-to-dark transition
Species
Zebrafish (Danio rerio)
Genotype
Wild type (pharmacological assay; no engineered allele)
Background
Larvae from 5 days post fertilization, assayed in standard 24-well plates
Publication
PMID:22197677
Pathograph links
GABA System Dysfunction perturbs fidelity: moderate Diazepam attenuates dark-flash-evoked thigmotaxis in larvae, and the anxiogenic reference compound caffeine enhances it, giving the assay bidirectional pharmacological validation of the benzodiazepine-GABA-A anxiolytic target at larval stages.
Limitations: Thigmotaxis is a behavioural proxy; no GABAergic transmission, receptor occupancy, or brain-region measurement was made, so the link is to the drug target of this node rather than to a demonstrated GABAergic deficit. Reducing the light-to-darkness contrast lowered thigmotaxis as effectively as diazepam did, so the readout is also sensitive to stimulus intensity and is not specific to pharmacology.
Readouts
Dark-flash-evoked larval thigmotaxis under diazepam
Thigmotaxis of 5-days-post-fertilization larvae following a sudden light-to-darkness transition, measured under diazepam against vehicle-treated larvae and against the anxiogenic comparator caffeine.
Direction: DECREASED
Interpretation: Attenuation by an anxiolytic together with enhancement by an anxiogenic is what validates the endpoint as an anxiety index rather than a general locomotor measure.
Show evidence (1 reference)
PMID:22197677 SUPPORT Model Organism
"Thigmotaxis was significantly attenuated by anxiolytic (diazepam) and significantly enhanced by anxiogenic (caffeine) drugs, thus representing the first validated thigmotaxis assay for larval zebrafish."
Reports the bidirectional pharmacological measurement behind this readout.
Show evidence (1 reference)
PMID:22197677 SUPPORT Model Organism
"We show that zebrafish larvae as young as 5 days post fertilization respond to this challenge by engaging in thigmotaxis."
Establishes that the anxiety-like endpoint this model links to the node is measurable at larval stages, which is what makes the assay a higher-throughput alternative to adult and rodent testing.
Retained alongside the adult novel-tank model rather than replacing it: the two assays use different developmental stages, different aversive stimuli, and different laboratories, so the shared diazepam result is independent corroboration rather than duplication.
Larval zebrafish edge-preference (thigmotaxis) assay
Automated imaging of larval preference for the edge of a multiwell plate, with and without a visual stimulus, used to dissociate anxiolytic drug classes. Diazepam, fluoxetine and caffeine were tested against the same endpoint, so the assay reports not only which compounds are active but which are not.
Anxiety-like edge preference (thigmotaxis) in a multiwell plate
Species
Zebrafish (Danio rerio)
Genotype
Wild type (pharmacological assay; no engineered allele)
Background
Larvae imaged in multiwell plates in five-fish and two-fish assay formats
Publication
PMID:22155488
Pathograph links
GABA System Dysfunction perturbs fidelity: moderate Diazepam reduces larval edge preference with or without visual stimuli, independently reproducing the benzodiazepine sensitivity seen in the dark-flash thigmotaxis and adult novel-tank assays.
Limitations: As with the other behavioural assays, the manipulation is pharmacological and the endpoint is positional: no GABAergic transmission was measured. The authors themselves note substantial zebrafish-human brain differences and claim conservation only at the level of the molecular signals that regulate anxiety.
Readouts
Larval edge preference under diazepam
Proportion of time larvae spend at the well edge under diazepam relative to controls, assayed both with and without a visual stimulus.
Direction: DECREASED
Interpretation: Reduction under both stimulus conditions indicates the benzodiazepine effect is on the anxiety-like state rather than on stimulus processing.
Show evidence (1 reference)
PMID:22155488 SUPPORT Model Organism
"Diazepam, a benzodiazepine that binds to GABA receptors, reduced the larval edge preference, with or without visual stimuli."
Reports the measurement behind this readout under both stimulus conditions.
Show evidence (1 reference)
PMID:22155488 SUPPORT Model Organism
"Although there are substantial differences between zebrafish and human brains, our results indicate that the signals that regulate anxiety are similar on a molecular level."
States the authors' own scope for transferring results from this model to human anxiety - molecular-signal conservation, with brain organization explicitly excluded.
Serotonin Dysregulation fails to recapitulate fidelity: low Acute fluoxetine, a selective serotonin reuptake inhibitor and the drug class that is first-line for human GAD, did not alter larval edge preference, while diazepam tested in the same assay did. The assay therefore does not reproduce the serotonergic arm of human GAD pharmacology.
Limitations: This negative result is not evidence against serotonergic involvement in GAD. Human SSRI anxiolysis emerges over weeks of dosing, so an acute immersion has no expectation of an effect, and the adult novel-tank model does detect acute 5-HT1A agonist anxiolysis with buspirone. The honest reading is that acute larval edge preference is insensitive to reuptake inhibition, which bounds the assay's use in screening serotonergic anxiolytics rather than adjudicating the mechanism.
Readouts
Larval edge preference under acute fluoxetine
Proportion of time larvae spend at the well edge under acute fluoxetine exposure relative to controls, assayed in the same experiment as the positive diazepam and caffeine comparators.
Direction: UNCHANGED
Interpretation: A negative result with internal positive controls in the same assay: the null is attributable to the compound class and exposure duration rather than to an insensitive endpoint.
Show evidence (1 reference)
PMID:22155488 SUPPORT Model Organism
"In contrast, fluoxetine, a selective serotonin reuptake inhibitor, did not affect the edge preference."
Directly reports the null measurement that grounds this readout, contrasted by the authors against the active comparators.
Show evidence (1 reference)
PMID:22155488 SUPPORT Model Organism
"These results suggest that the edge preference in zebrafish larvae is a measure of anxiety and further illustrate that the pharmaceuticals used in the study have different mechanisms of action."
Supports treating the compound-level dissociation, including the fluoxetine null, as an interpretable property of the assay rather than an experimental failure.
The fluoxetine null is curated deliberately. Recording only the compounds that worked would misrepresent this assay as a general anxiolytic screen when the source reports a dissociation between drug classes.
{ }

Source YAML

click to show 
name: Generalized Anxiety Disorder
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Generalized anxiety disorder (GAD) is a chronic psychiatric disorder
  characterized by excessive, difficult-to-control worry about multiple domains,
  accompanied by restlessness, fatigue, irritability, muscle tension, and sleep
  disturbance. Its pathophysiology involves amygdala hyperactivity with impaired
  prefrontal regulation, GABAergic and serotonergic system dysfunction,
  hypothalamic-pituitary-adrenal axis dysregulation, and noradrenergic
  hyperactivity.
category: Complex
parents:
- Psychiatric Disease
disease_term:
  preferred_term: generalized anxiety disorder
  term:
    id: MONDO:0001942
    label: generalized anxiety disorder
pathophysiology:
- name: Amygdala Hyperactivity
  description: >
    Exaggerated amygdala response to perceived threats leads to
    excessive fear and anxiety. Reduced prefrontal cortex regulation
    of amygdala activity.
  cell_types:
  - preferred_term: Amygdala Pyramidal Neuron
    term:
      id: CL:4023110
      label: amygdala pyramidal neuron
  biological_processes:
  - preferred_term: Fear Response
    term:
      id: GO:0042596
      label: fear response
  evidence:
  - reference: PMID:38865810
    reference_title: "GABAergic implications in anxiety and related disorders."
    supports: SUPPORT
    snippet: "Evidence indicates that anxiety disorders arise from an imbalance in
      the functioning of brain circuits that govern the modulation of emotional responses
      to possibly threatening stimuli. The circuits under consideration in this context
      include the amygdala's bottom-up activity, which signifies the existence of
      stimuli that may be seen as dangerous. Moreover, these circuits encompass top-down
      regulatory processes that originate in the prefrontal cortex, facilitating the
      communication of the emotional significance associated with the inputs."
    explanation: This evidence supports the model of amygdala hyperactivity in
      anxiety and the role of prefrontal cortex in regulating amygdala responses
      to threat stimuli.
- name: GABA System Dysfunction
  description: >
    Reduced GABAergic inhibition contributes to neuronal hyperexcitability
    and anxiety. Benzodiazepines enhance GABA function.
  cell_types:
  - preferred_term: GABAergic Interneuron
    term:
      id: CL:0011005
      label: GABAergic interneuron
  biological_processes:
  - preferred_term: GABAergic Transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  evidence:
  - reference: PMID:38865810
    reference_title: "GABAergic implications in anxiety and related disorders."
    supports: SUPPORT
    snippet: "A decrease in GABAergic activity is present in both anxiety disorders
      and severe depression. Research on cerebral functional imaging in depressive
      individuals has shown reduced levels of GABA within the cortical regions. Additionally,
      animal studies demonstrated that a reduction in the expression of GABAA/B receptors
      results in a behavioral pattern resembling anxiety."
    explanation: This evidence demonstrates reduced GABAergic activity in
      anxiety disorders through both imaging studies and animal models showing
      that decreased GABA receptor expression leads to anxiety-like behavior.
  - reference: PMID:38865810
    reference_title: "GABAergic implications in anxiety and related disorders."
    supports: SUPPORT
    snippet: "The amygdala consists of inhibitory networks composed of GABAergic interneurons,
      responsible for modulating anxiety responses in both normal and pathological
      conditions. The GABAA receptor has allosteric sites (e.g., α/γ, γ/β, and α/β)
      which enable regulation of neuronal inhibition in the amygdala. These sites
      serve as molecular targets for anxiolytic medications such as benzodiazepine
      and barbiturates."
    explanation: This supports the mechanism of GABAergic dysfunction in the
      amygdala and explains how benzodiazepines work by targeting GABAA receptor
      allosteric sites to enhance inhibition.
  - reference: PMID:39294497
    reference_title: "Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study."
    supports: NO_EVIDENCE
    snippet: "We leveraged information from more than 1.2 million participants, including
      97,383 cases, to investigate the genetics of anxiety disorders across five continental
      groups. Through ancestry-specific and cross-ancestry genome-wide association
      studies, we identified 51 anxiety-associated loci, 39 of which were novel."
    explanation: This snippet supports broad genetic architecture of anxiety
      disorders but does not directly provide evidence for GABA system
      dysfunction.
  - reference: PMID:19643124
    reference_title: "Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Diazepam another benzodiazepine anxiolytic drug did produce an anxiolytic
      effect at doses that did not cause sedation. The zebrafish novel tank diving
      task can be useful in discriminating anxiolytic drugs of several classes (serotonergic,
      benzodiazepines and nicotinic)."
    explanation: New Approach Methodology (NAM) evidence — the zebrafish novel-tank
      diving assay, an animal-model alternative for behavioral pharmacology screening,
      shows that the benzodiazepine diazepam (a GABA-A receptor agonist) produces a
      dose-dependent anxiolytic effect, supporting functional conservation of the
      GABAergic/benzodiazepine anxiolytic target relevant to GAD. (Chlordiazepoxide
      did not produce anxiolysis in the same assay, illustrating compound-level
      discrimination by the model.)
- name: Serotonin Dysregulation
  description: >
    Altered serotonin signaling, particularly in raphe-prefrontal
    circuits, contributes to anxiety. SSRIs are first-line treatment.
  cell_types:
  - preferred_term: Serotonergic Neuron
    term:
      id: CL:0000850
      label: serotonergic neuron
  biological_processes:
  - preferred_term: Serotonin Signaling
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:24936175
    reference_title: "Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression."
    supports: SUPPORT
    snippet: "Decreased serotonergic activity has been implicated in anxiety and major
      depression, and antidepressants directly or indirectly increase the long-term
      activity of the serotonin system. A key component of serotonin circuitry is
      the 5-HT1A autoreceptor, which functions as the major somatodendritic autoreceptor
      to negatively regulate the 'gain' of the serotonin system."
    explanation: This evidence establishes the role of decreased serotonergic
      activity in anxiety and explains how antidepressants work by increasing
      serotonin system activity.
  - reference: PMID:24936175
    reference_title: "Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression."
    supports: SUPPORT
    snippet: "In addition, 5-HT1A heteroreceptors are abundantly expressed post-synaptically
      in the prefrontal cortex (PFC), amygdala, and hippocampus to mediate serotonin
      actions on fear, anxiety, stress, and cognition."
    explanation: This supports the specific role of serotonin signaling in
      prefrontal-limbic circuits that regulate anxiety and fear responses.
  - reference: PMID:19643124
    reference_title: "Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Buspirone, a serotonergic (5HT(1A) receptor agonist) anxiolytic drug
      with some D(2) dopaminergic effect, had a pronounced anxiolytic-like effect in
      the zebrafish diving model at doses that did not have sedative effects."
    explanation: New Approach Methodology (NAM) evidence — in the zebrafish novel-tank
      diving assay, the 5-HT1A receptor agonist buspirone produces a pronounced
      anxiolytic-like effect at non-sedative doses, supporting functional conservation
      of serotonergic (5-HT1A) anxiolytic signaling and the utility of this animal-model
      alternative for screening serotonergic anxiolytics relevant to GAD.
- name: HPA Axis Dysregulation
  description: >
    Chronic activation of the stress response system with elevated
    cortisol contributes to sustained anxiety and physical symptoms.
  biological_processes:
  - preferred_term: Stress Response
    term:
      id: GO:0006950
      label: response to stress
  evidence:
  - reference: PMID:20808146
    reference_title: "Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram."
    supports: SUPPORT
    snippet: "Generalized anxiety disorder (GAD) is a common disorder in older adults,
      which has been linked to hyperactivity of the hypothalamic-pituitary-adrenal
      (HPA) axis in this age group."
    explanation: This evidence directly links GAD to HPA axis hyperactivity,
      particularly in older adults.
  - reference: PMID:20808146
    reference_title: "Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram."
    supports: SUPPORT
    snippet: "Compared with placebo-treated patients, SSRI-treated patients had a
      significantly greater reduction in both peak and total cortisol. This reduction
      in cortisol was limited to patients with elevated (above the median) baseline
      cortisol, in whom SSRI-treated patients showed substantially greater reduction
      in cortisol than did placebo-treated patients. Reductions in cortisol were associated
      with improvements in anxiety."
    explanation: This demonstrates that HPA axis hyperactivity with elevated
      cortisol is present in GAD patients and that successful treatment reduces
      cortisol levels in parallel with anxiety symptom reduction.
- name: Noradrenergic Hyperactivity
  description: >
    Elevated norepinephrine activity in locus coeruleus contributes
    to hyperarousal and somatic symptoms of anxiety.
  cell_types:
  - preferred_term: Noradrenergic Neuron
    term:
      id: CL:0008025
      label: noradrenergic neuron
- name: Oxidative Stress
  description: >
    Increased oxidative stress markers and reduced antioxidant enzyme
    activity in GAD patients. Elevated malondialdehyde and reduced
    superoxide dismutase correlate with symptom severity.
  evidence:
  - reference: PMID:38204917
    reference_title: "Biological Markers in Newly Diagnosed Generalized Anxiety Disorder Patients: 8-OHdG, S100B and Oxidative Stress."
    supports: SUPPORT
    snippet: "The 8-OHdG values of the GAD group were determined to be statistically
      significantly higher than those of the control group (p=0.028)."
    explanation: This demonstrates elevated oxidative DNA damage in GAD patients
      as measured by 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative
      stress.
  - reference: PMID:38204917
    reference_title: "Biological Markers in Newly Diagnosed Generalized Anxiety Disorder Patients: 8-OHdG, S100B and Oxidative Stress."
    supports: SUPPORT
    snippet: "The results of this study showed that there could be DNA damage because
      of oxidative stress in GAD patients."
    explanation: This concludes that oxidative stress contributes to the
      pathophysiology of GAD through DNA damage mechanisms.
- name: Epigenetic Alterations
  description: >
    DNA methylation changes in anxiety-related genes, particularly in
    monocytes and granulocytes. Methylation sites identified in genes
    involved in neurogenesis and fear memory.
  cell_types:
  - preferred_term: Monocyte
    term:
      id: CL:0000576
      label: monocyte
  - preferred_term: Granulocyte
    term:
      id: CL:0000094
      label: granulocyte
  evidence:
  - reference: PMID:37542162
    reference_title: "Methylome-wide association study of anxiety disorders."
    supports: SUPPORT
    snippet: "Applying an enrichment-based sequencing approach covering nearly 28
      million autosomal CpG sites, we conducted a methylome-wide association study
      (MWAS) of lifetime ANX in 1132 participants (618 cases/514 controls) from the
      Netherlands Study of Depression and Anxiety. Using epigenomic deconvolution,
      we performed MWAS for the main cell types in blood: granulocytes, T-cells, B-cells
      and monocytes. Cell-type specific analyses identified 280 and 82 methylome-wide
      significant associations (q-value < 0.1) in monocytes and granulocytes, respectively."
    explanation: This large-scale epigenome-wide study identifies hundreds of
      significant DNA methylation sites associated with anxiety disorders,
      supporting the role of epigenetic mechanisms in GAD pathophysiology.
  - reference: PMID:37542162
    reference_title: "Methylome-wide association study of anxiety disorders."
    supports: SUPPORT
    snippet: "In monocytes, two specific sites in the FZR1 gene showed significant
      replication after Bonferroni correction with an additional 15 nominally replicated
      sites in monocytes and 4 in T-cells. FZR1 regulates neurogenesis in the hippocampus,
      and its knockout leads to impairments in associative fear memory and long-term
      potentiation in mice."
    explanation: This identifies FZR1 as a key gene with replicable methylation
      changes in anxiety, linking epigenetic alterations to hippocampal
      neurogenesis and fear memory mechanisms.
phenotypes:
- name: Excessive Worry
  category: Psychiatric
  description: >-
    Persistent, excessive, and difficult-to-control apprehension about
    everyday events and activities is the core diagnostic feature of GAD.
    The worry is disproportionate to actual circumstances and is sustained
    most days for at least six months, distinguishing it from normal,
    transient anxiety.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Persistent, difficult to control
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:39294497
    reference_title: "Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study."
    supports: NO_EVIDENCE
    snippet: "The heritability of anxiety was enriched for genes expressed in the
      limbic system, cerebral cortex, cerebellum, metencephalon, entorhinal cortex
      and brain stem."
    explanation: This snippet supports genetic architecture of anxiety disorders
      but does not directly evidence the specific clinical phenotype of
      excessive worry.
- name: Restlessness
  category: Psychiatric
  description: >-
    A pervasive sense of feeling keyed up, on edge, or unable to settle is a
    common somatic manifestation of GAD. This state of motor and psychic
    tension reflects chronic hyperarousal and frequently accompanies the
    excessive worry that defines the disorder.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Restlessness
    term:
      id: HP:0000711
      label: Restlessness
- name: Fatigue
  category: Systemic
  description: >-
    Persistent tiredness and being easily fatigued are recognized somatic
    symptoms of GAD, reflecting the metabolic and physical toll of sustained
    hyperarousal and chronic muscle tension. Fatigue is frequently compounded
    by the sleep disturbance commonly seen in affected patients.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- name: Difficulty Concentrating
  category: Neurological
  description: >-
    Patients with GAD often report impaired concentration or a sensation of
    the mind going blank, as intrusive worry competes for cognitive
    resources. This attentional disruption can interfere with work, study,
    and daily functioning and is part of the diagnostic symptom cluster.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Poor Concentration
    term:
      id: HP:0000736
      label: Short attention span
- name: Muscle Tension
  category: Musculoskeletal
  description: >-
    Chronic muscle tension, stiffness, and aching are characteristic somatic
    features of GAD, driven by sustained sympathetic and noradrenergic
    hyperactivity. This tension commonly affects the neck, shoulders, and
    back and contributes to headaches and physical fatigue in affected
    patients.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Muscle Tension
    term:
      id: HP:0003552
      label: Muscle stiffness
- name: Sleep Disturbance
  category: Psychiatric
  description: >-
    Difficulty falling asleep, staying asleep, or experiencing restless and
    unsatisfying sleep is a frequent feature of GAD. Nocturnal worry and
    physiological hyperarousal disrupt sleep continuity, and the resulting
    sleep deprivation can further amplify daytime anxiety and irritability.
  frequency: FREQUENT
  notes: Difficulty falling or staying asleep
  phenotype_term:
    preferred_term: Insomnia
    term:
      id: HP:0002360
      label: Sleep disturbance
- name: Irritability
  category: Psychiatric
  description: >-
    Heightened irritability and a reduced threshold for frustration are
    common in GAD, reflecting the cumulative strain of chronic worry,
    hyperarousal, and impaired sleep. This symptom can affect interpersonal
    relationships and is included among the core associated features of the
    disorder.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
biochemical:
- name: Cortisol
  presence: Elevated
  context: Chronic stress activation
- name: GABA
  presence: Decreased
  context: Reduced inhibitory tone
genetic:
- name: SLC6A4
  gene_term:
    preferred_term: SLC6A4
    term:
      id: hgnc:11050
      label: SLC6A4
  association: Risk Factor
  notes: Serotonin transporter
- name: COMT
  gene_term:
    preferred_term: COMT
    term:
      id: hgnc:2228
      label: COMT
  association: Risk Factor
  notes: Catecholamine metabolism
- name: CRHR1
  gene_term:
    preferred_term: CRHR1
    term:
      id: hgnc:2357
      label: CRHR1
  association: Risk Factor
  notes: CRH receptor
- name: NPY
  gene_term:
    preferred_term: NPY
    term:
      id: hgnc:7955
      label: NPY
  association: Risk Factor
  notes: Neuropeptide Y
environmental:
- name: Childhood Adversity
  exposure_term:
    preferred_term: psychological stress
    term:
      id: XCO:0001265
      label: stress
  notes: Major risk factor
  evidence:
  - reference: PMID:25089514
    reference_title: "Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GAD was associated with stressful life events in childhood and adulthood, and personality"
    explanation: Systematic review of cohort studies finds childhood stressful life events among the psychosocial risk factors for GAD onset.
- name: Chronic Stress
  exposure_term:
    preferred_term: psychological stress
    term:
      id: XCO:0001265
      label: stress
  notes: Precipitates and maintains
  evidence:
  - reference: PMID:29503978
    reference_title: "The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased cumulative effects of stress on the human body (allostatic load) are linked to many adverse health consequences, including psychiatric illnesses such as GAD"
    explanation: Review of GAD neurobiology links the cumulative burden of chronic stress (allostatic load) specifically to GAD, supporting chronic stress as a precipitating exposure for this disease.
- name: Trauma
  notes: Can trigger onset
  evidence:
  - reference: PMID:9166642
    reference_title: "Preliminary investigation of the role of previous exposure to potentially traumatizing events in generalized anxiety disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GAD individuals were found to be more likely than nonanxious controls to report exposure to a potentially traumatizing event"
    explanation: Study finds GAD patients report greater prior exposure to potentially traumatizing events than nonanxious controls.
- name: Caffeine
  exposure_term:
    preferred_term: caffeine exposure
    term:
      id: ECTO:9000205
      label: exposure to caffeine
  notes: Can exacerbate symptoms
  evidence:
  - reference: PMID:1444724
    reference_title: "Anxiogenic effects of caffeine in patients with anxiety disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with GAD are abnormally sensitive to caffeine"
    explanation: Controlled trial finds GAD patients show abnormal anxiogenic sensitivity to oral caffeine compared to normal subjects.
treatments:
- name: SSRIs
  description: First-line pharmacotherapy (escitalopram, sertraline,
    paroxetine).
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: escitalopram
      term:
        id: CHEBI:36791
        label: escitalopram
- name: SNRIs
  description: Alternative first-line (venlafaxine, duloxetine).
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: venlafaxine
      term:
        id: CHEBI:9943
        label: venlafaxine
- name: Buspirone
  description: Non-benzodiazepine anxiolytic, no dependence risk.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: buspirone
      term:
        id: CHEBI:3223
        label: buspirone
- name: Benzodiazepines
  description: Short-term use for severe symptoms, dependence risk.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: benzodiazepine
      term:
        id: NCIT:C1012
        label: Benzodiazepine
- name: Pregabalin
  description: Effective in GAD, approved in Europe.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pregabalin
      term:
        id: CHEBI:64356
        label: pregabalin
- name: Cognitive Behavioral Therapy
  description: First-line psychotherapy, addresses worry and avoidance.
  treatment_term:
    preferred_term: Cognitive Behavior Therapy
    term:
      id: NCIT:C64345
      label: Cognitive Behavior Therapy
- name: Relaxation Training
  description: Progressive muscle relaxation, breathing exercises.
  treatment_term:
    preferred_term: Relaxation Therapy
    term:
      id: NCIT:C15316
      label: Relaxation Therapy
- name: Mindfulness-Based Therapy
  description: Reduces worry and rumination.
  treatment_term:
    preferred_term: Mindfulness Relaxation
    term:
      id: NCIT:C93327
      label: Mindfulness Relaxation
animal_models:
- name: Adult zebrafish novel tank diving anxiolytic-screening assay
  species: Zebrafish (Danio rerio)
  genotype: Wild type (pharmacological assay; no engineered allele)
  description: >-
    Adult zebrafish placed in a novel tank initially dwell in the bottom third
    and progressively explore higher levels of the tank. The proportion of time
    spent bottom-dwelling serves as the anxiety index, while swim speed is
    recorded in parallel so that sedation can be separated from anxiolysis.
    Drugs are given by brief immersion rather than injection. As a New Approach
    Methodology-tier behavioural pharmacology screen the assay is inexpensive
    and higher-throughput than its rodent equivalents, and it discriminates
    anxiolytic drugs across serotonergic, benzodiazepine and nicotinic classes.
  publication: PMID:19643124
  associated_phenotypes:
  - Anxiety-like bottom dwelling (diving response) in a novel environment
  modeled_mechanisms:
  - target: Serotonin Dysregulation
    relationship: PERTURBS
    fidelity: MODERATE
    description: >-
      Acute immersion in the 5-HT1A receptor agonist buspirone reduces the
      diving response at doses that do not slow swimming, showing that the
      serotonergic (5-HT1A) anxiolytic target underlying this node is
      functionally conserved and pharmacologically addressable in zebrafish.
    limitations: >-
      Buspirone also carries D2 dopaminergic activity, so the effect cannot be
      attributed to 5-HT1A signalling alone, and a single 3-minute immersion
      cannot model the weeks of treatment that human serotonergic anxiolysis
      requires. The assay demonstrates conservation of an anxiolytic drug
      target, not that zebrafish reproduce the raphe-prefrontal serotonergic
      pathology curated for human GAD.
    readouts:
    - name: Novel-tank bottom dwelling under buspirone
      target: Serotonin Dysregulation
      description: >-
        Time spent in the bottom third of the novel tank across a 5-minute
        session after brief buspirone immersion, compared with vehicle controls,
        with swim speed measured concurrently as a sedation control.
      direction: DECREASED
      interpretation: >-
        A fall in bottom dwelling with no concurrent fall in swim speed is read
        as anxiolysis rather than sedation, so the readout reports specifically
        on pharmacological engagement of the serotonergic arm.
      evidence:
      - reference: PMID:19643124
        reference_title: "Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Buspirone, a serotonergic (5HT(1A) receptor agonist) anxiolytic
          drug with some D(2) dopaminergic effect, had a pronounced anxiolytic-like
          effect in the zebrafish diving model at doses that did not have sedative
          effects."
        explanation: Reports the dose-controlled behavioural measurement behind
          this readout, including the explicit absence of sedation at the
          effective doses.
    evidence:
    - reference: PMID:19643124
      reference_title: "Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The zebrafish novel tank diving task can be useful in discriminating
        anxiolytic drugs of several classes (serotonergic, benzodiazepines and nicotinic)."
      explanation: Supports treating this assay as informative for the
        serotonergic arm of GAD pharmacology, since the authors' stated claim is
        class-level discrimination that includes serotonergic anxiolytics.
  - target: GABA System Dysfunction
    relationship: PERTURBS
    fidelity: MODERATE
    description: >-
      The benzodiazepine diazepam reduces the diving response at non-sedative
      doses, indicating that benzodiazepine-GABA-A signalling is present and
      anxiolytically effective in zebrafish. The second benzodiazepine tested,
      chlordiazepoxide, produced sedation but no anxiolysis, so the model
      engages this node only partially.
    limitations: >-
      Chlordiazepoxide is an effective GABA-A agonist and is anxiolytic in
      rodents, yet produced no reduction in bottom dwelling here over a broad
      dose range; the diazepam dose-response was also biphasic. Benzodiazepine
      responsiveness is therefore compound-specific in this model, and a
      negative result for a GABAergic compound must not be transferred to human
      GAD as evidence against a GABAergic mechanism.
    readouts:
    - name: Novel-tank bottom dwelling under diazepam
      target: GABA System Dysfunction
      description: >-
        Time spent in the bottom third of the novel tank after brief diazepam
        immersion, compared with vehicle controls, with swim speed measured
        concurrently as a sedation control.
      direction: DECREASED
      interpretation: >-
        Anxiolysis at doses that leave swimming intact is the positive readout
        for functional benzodiazepine-GABA-A signalling in this model.
      evidence:
      - reference: PMID:19643124
        reference_title: "Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Diazepam another benzodiazepine anxiolytic drug did produce an
          anxiolytic effect at doses that did not cause sedation."
        explanation: Reports the measurement behind this readout, with sedation
          explicitly excluded as the explanation.
    - name: Novel-tank bottom dwelling under chlordiazepoxide
      target: GABA System Dysfunction
      description: >-
        The same bottom-dwelling measure after chlordiazepoxide immersion across
        a dose range extending up to sedative concentrations.
      direction: UNCHANGED
      interpretation: >-
        A genuine negative result: the compound reached behaviourally active
        concentrations (it caused sedation) without producing anxiolysis, so the
        null is not explained by failure to reach the target tissue. This bounds
        how far benzodiazepine pharmacology in this model may be generalized.
      evidence:
      - reference: PMID:19643124
        reference_title: "Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "In contrast, chlordiazepoxide, a benzodiazepine anxiolytic drug,
          which is an effective agonist at GABA-A receptors, did not produce signs
          of anxiolysis in zebrafish over a broad dose range up to those that caused
          sedation."
        explanation: Documents the negative readout and confirms the compound was
          behaviourally active at the doses tested.
    evidence:
    - reference: PMID:19643124
      reference_title: "Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The zebrafish novel tank diving task can be useful in discriminating
        anxiolytic drugs of several classes (serotonergic, benzodiazepines and nicotinic)."
      explanation: Supports the assay as informative for benzodiazepine-GABA-A
        pharmacology, but only partially, because one of the two benzodiazepines
        tested failed to produce anxiolysis.
  notes: >-
    Scope is limited to the two neurotransmitter mechanisms the publication
    actually manipulated. The model is deliberately not linked to Amygdala
    Hyperactivity, HPA Axis Dysregulation, or the disease-level phenotypes,
    because no neural, endocrine, or symptom-level measurement was made.
- name: Larval zebrafish dark-flash thigmotaxis assay
  species: Zebrafish (Danio rerio)
  genotype: Wild type (pharmacological assay; no engineered allele)
  background: Larvae from 5 days post fertilization, assayed in standard 24-well plates
  description: >-
    Thigmotaxis ("wall-hugging") in 5-days-post-fertilization larvae, triggered
    by a sudden light-to-darkness transition and scored in a standard 24-well
    plate over a 10-minute session. This is the larval, plate-based tier of
    zebrafish anxiety modelling and the closest zebrafish analogue of a New
    Approach Methodology: it runs at medium-to-high throughput on early-stage
    larvae and reads out with both anxiolytic and anxiogenic reference compounds.
  publication: PMID:22197677
  associated_phenotypes:
  - Anxiety-like thigmotaxis (wall-hugging) after a sudden light-to-dark transition
  modeled_mechanisms:
  - target: GABA System Dysfunction
    relationship: PERTURBS
    fidelity: MODERATE
    description: >-
      Diazepam attenuates dark-flash-evoked thigmotaxis in larvae, and the
      anxiogenic reference compound caffeine enhances it, giving the assay
      bidirectional pharmacological validation of the benzodiazepine-GABA-A
      anxiolytic target at larval stages.
    limitations: >-
      Thigmotaxis is a behavioural proxy; no GABAergic transmission, receptor
      occupancy, or brain-region measurement was made, so the link is to the
      drug target of this node rather than to a demonstrated GABAergic deficit.
      Reducing the light-to-darkness contrast lowered thigmotaxis as effectively
      as diazepam did, so the readout is also sensitive to stimulus intensity
      and is not specific to pharmacology.
    readouts:
    - name: Dark-flash-evoked larval thigmotaxis under diazepam
      target: GABA System Dysfunction
      description: >-
        Thigmotaxis of 5-days-post-fertilization larvae following a sudden
        light-to-darkness transition, measured under diazepam against
        vehicle-treated larvae and against the anxiogenic comparator caffeine.
      direction: DECREASED
      interpretation: >-
        Attenuation by an anxiolytic together with enhancement by an anxiogenic
        is what validates the endpoint as an anxiety index rather than a general
        locomotor measure.
      evidence:
      - reference: PMID:22197677
        reference_title: Measuring thigmotaxis in larval zebrafish.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Thigmotaxis was significantly attenuated by anxiolytic (diazepam)
          and significantly enhanced by anxiogenic (caffeine) drugs, thus representing
          the first validated thigmotaxis assay for larval zebrafish."
        explanation: Reports the bidirectional pharmacological measurement behind
          this readout.
    evidence:
    - reference: PMID:22197677
      reference_title: Measuring thigmotaxis in larval zebrafish.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We show that zebrafish larvae as young as 5 days post fertilization
        respond to this challenge by engaging in thigmotaxis."
      explanation: Establishes that the anxiety-like endpoint this model links to
        the node is measurable at larval stages, which is what makes the assay a
        higher-throughput alternative to adult and rodent testing.
  notes: >-
    Retained alongside the adult novel-tank model rather than replacing it: the
    two assays use different developmental stages, different aversive stimuli,
    and different laboratories, so the shared diazepam result is independent
    corroboration rather than duplication.
- name: Larval zebrafish edge-preference (thigmotaxis) assay
  species: Zebrafish (Danio rerio)
  genotype: Wild type (pharmacological assay; no engineered allele)
  background: Larvae imaged in multiwell plates in five-fish and two-fish assay formats
  description: >-
    Automated imaging of larval preference for the edge of a multiwell plate,
    with and without a visual stimulus, used to dissociate anxiolytic drug
    classes. Diazepam, fluoxetine and caffeine were tested against the same
    endpoint, so the assay reports not only which compounds are active but which
    are not.
  publication: PMID:22155488
  associated_phenotypes:
  - Anxiety-like edge preference (thigmotaxis) in a multiwell plate
  modeled_mechanisms:
  - target: GABA System Dysfunction
    relationship: PERTURBS
    fidelity: MODERATE
    description: >-
      Diazepam reduces larval edge preference with or without visual stimuli,
      independently reproducing the benzodiazepine sensitivity seen in the
      dark-flash thigmotaxis and adult novel-tank assays.
    limitations: >-
      As with the other behavioural assays, the manipulation is pharmacological
      and the endpoint is positional: no GABAergic transmission was measured.
      The authors themselves note substantial zebrafish-human brain differences
      and claim conservation only at the level of the molecular signals that
      regulate anxiety.
    readouts:
    - name: Larval edge preference under diazepam
      target: GABA System Dysfunction
      description: >-
        Proportion of time larvae spend at the well edge under diazepam relative
        to controls, assayed both with and without a visual stimulus.
      direction: DECREASED
      interpretation: >-
        Reduction under both stimulus conditions indicates the benzodiazepine
        effect is on the anxiety-like state rather than on stimulus processing.
      evidence:
      - reference: PMID:22155488
        reference_title: "On the edge: pharmacological evidence for anxiety-related behavior in zebrafish larvae."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Diazepam, a benzodiazepine that binds to GABA receptors, reduced
          the larval edge preference, with or without visual stimuli."
        explanation: Reports the measurement behind this readout under both
          stimulus conditions.
    evidence:
    - reference: PMID:22155488
      reference_title: "On the edge: pharmacological evidence for anxiety-related behavior in zebrafish larvae."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Although there are substantial differences between zebrafish and
        human brains, our results indicate that the signals that regulate anxiety
        are similar on a molecular level."
      explanation: States the authors' own scope for transferring results from
        this model to human anxiety - molecular-signal conservation, with brain
        organization explicitly excluded.
  - target: Serotonin Dysregulation
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      Acute fluoxetine, a selective serotonin reuptake inhibitor and the drug
      class that is first-line for human GAD, did not alter larval edge
      preference, while diazepam tested in the same assay did. The assay
      therefore does not reproduce the serotonergic arm of human GAD
      pharmacology.
    limitations: >-
      This negative result is not evidence against serotonergic involvement in
      GAD. Human SSRI anxiolysis emerges over weeks of dosing, so an acute
      immersion has no expectation of an effect, and the adult novel-tank model
      does detect acute 5-HT1A agonist anxiolysis with buspirone. The honest
      reading is that acute larval edge preference is insensitive to reuptake
      inhibition, which bounds the assay's use in screening serotonergic
      anxiolytics rather than adjudicating the mechanism.
    readouts:
    - name: Larval edge preference under acute fluoxetine
      target: Serotonin Dysregulation
      description: >-
        Proportion of time larvae spend at the well edge under acute fluoxetine
        exposure relative to controls, assayed in the same experiment as the
        positive diazepam and caffeine comparators.
      direction: UNCHANGED
      interpretation: >-
        A negative result with internal positive controls in the same assay: the
        null is attributable to the compound class and exposure duration rather
        than to an insensitive endpoint.
      evidence:
      - reference: PMID:22155488
        reference_title: "On the edge: pharmacological evidence for anxiety-related behavior in zebrafish larvae."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "In contrast, fluoxetine, a selective serotonin reuptake inhibitor,
          did not affect the edge preference."
        explanation: Directly reports the null measurement that grounds this
          readout, contrasted by the authors against the active comparators.
    evidence:
    - reference: PMID:22155488
      reference_title: "On the edge: pharmacological evidence for anxiety-related behavior in zebrafish larvae."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These results suggest that the edge preference in zebrafish larvae
        is a measure of anxiety and further illustrate that the pharmaceuticals used
        in the study have different mechanisms of action."
      explanation: Supports treating the compound-level dissociation, including
        the fluoxetine null, as an interpretable property of the assay rather
        than an experimental failure.
  notes: >-
    The fluoxetine null is curated deliberately. Recording only the compounds
    that worked would misrepresent this assay as a general anxiolytic screen
    when the source reports a dissociation between drug classes.
discussions:
- discussion_id: gad_zebrafish_anxiolytic_class_mismatch
  prompt: >-
    Do zebrafish anxiolytic assays report the human GAD treatment hierarchy, given
    that acute SSRI exposure and the GABA-A agonist chlordiazepoxide both fail to
    produce anxiolysis in them while buspirone and diazepam succeed?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Serotonin Dysregulation
  - pathophysiology#GABA System Dysfunction
  rationale: >-
    Across the three zebrafish assays curated here the pharmacological pattern
    does not match human GAD practice. SSRIs are first-line in humans, yet acute
    fluoxetine leaves larval edge preference unchanged; chlordiazepoxide is an
    effective GABA-A agonist and is anxiolytic in rodents, yet produces sedation
    without anxiolysis in the adult novel-tank assay; while buspirone and
    diazepam are active in both. Two explanations are compatible with the data
    and are not distinguished by it - an exposure-duration artefact (acute
    immersion cannot express the weeks-long adaptation human SSRI anxiolysis
    requires) or genuine divergence in receptor-level pharmacology between
    teleost and mammalian anxiety circuits. Which it is determines whether these
    assays may be used to screen serotonergic anxiolytics at all, so it should be
    resolved rather than left implicit in the per-model limitations.
  proposed_experiments:
  - experiment_id: gad_zebrafish_chronic_ssri_exposure
    name: Sub-chronic versus acute SSRI exposure in larval and adult zebrafish anxiety assays
    description: >-
      Run matched dose-response curves for fluoxetine under acute immersion and
      under multi-day waterborne exposure in both the larval edge-preference and
      adult novel-tank assays, with diazepam and buspirone as in-assay positive
      controls and swim speed as a sedation control throughout.
    decision_criterion: >-
      Whether anxiolysis appears under sub-chronic but not acute exposure, at
      doses that leave locomotion intact.
    supporting_outcome:
    - >-
      Anxiolysis emerging only after sustained exposure would show the null is an
      exposure-duration artefact, leaving the assays usable for serotonergic
      screening provided the dosing schedule is matched to the human one.
    refuting_outcome:
    - >-
      A persistent null under sustained exposure at non-sedative doses would
      indicate genuine divergence in serotonergic anxiolytic pharmacology and
      argue against using these assays to screen reuptake inhibitors.
  notes: >-
    Raised while adding structured animal-model links for issue #4873; the
    underlying results were already cited on the GABA and serotonin nodes but the
    conflict between them had not been recorded anywhere.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
- accession: geo:GSE61672
  title: Blood gene expression profiles associated with symptoms of generalized anxiety disorder
  description: Prospective epidemiological studies found that generalized anxiety disorder (GAD) can impair immune function and increase risk for cardiovascular disease or events. Mechanisms underlying the physiological reververations of anxiety, however, are still elusive. Hence, we aimed to investigate molecular processes mediating effects of anxiety on physical health using blood gene expression profiles of 546 community participants. Of these, 179 met the status of controls and 157 cases of anxiety.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 546
  publication: PMID:25300922
  notes: Identified by GEO DataSets index search for Generalized Anxiety Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
references:
- reference: DOI:10.1002/wps.21078
  title: 'Candidate biomarkers in psychiatric disorders: state of the field'
  findings: []
- reference: DOI:10.1038/s41380-023-02205-w
  title: Methylome-wide association study of anxiety disorders
  findings: []
- reference: DOI:10.1038/s41588-024-01908-2
  title: Gene discovery and biological insights into anxiety disorders from a
    large-scale multi-ancestry genome-wide association study
  findings: []
- reference: DOI:10.1038/s41598-025-90362-z
  title: The power spectrum and functional connectivity characteristics of
    resting-state EEG in patients with generalized anxiety disorder
  findings: []
- reference: DOI:10.1101/2024.07.03.24309466
  title: Genome-wide association study of major anxiety disorders in 122,341
    European-ancestry cases identifies 58 loci and highlights GABAergic
    signaling
  findings: []
- reference: DOI:10.1101/2024.09.07.24313247
  title: Oxidative stress markers predict treatment outcomes in patients with
    generalized anxiety disorder treated with selective serotonin reuptake
    inhibitors
  findings: []
- reference: DOI:10.3390/ijms26115417
  title: 'Molecular Basis of Anxiety: A Comprehensive Review of 2014–2024 Clinical
    and Preclinical Studies'
  findings: []
- reference: DOI:10.3390/nu16203564
  title: 'Effect of Probiotics Supplementation on Cortisol Levels: A Systematic Review
    and Meta-Analysis'
  findings: []
- reference: DOI:10.3758/s13415-024-01162-3
  title: Understanding the heterogeneity of anxiety using a translational
    neuroscience approach
  findings: []
- reference: DOI:10.4236/psych.2023.141003
  title: 'Generalized Anxiety Disorder: A Review of Current Literature in Saudi Arabia'
  findings: []
📚

References & Deep Research

References

10
DOI:10.1002/wps.21078
Candidate biomarkers in psychiatric disorders: state of the field
No top-level findings curated for this source.
DOI:10.1038/s41380-023-02205-w
Methylome-wide association study of anxiety disorders
No top-level findings curated for this source.
DOI:10.1038/s41588-024-01908-2
Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study
No top-level findings curated for this source.
DOI:10.1038/s41598-025-90362-z
The power spectrum and functional connectivity characteristics of resting-state EEG in patients with generalized anxiety disorder
No top-level findings curated for this source.
DOI:10.1101/2024.07.03.24309466
Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling
No top-level findings curated for this source.
DOI:10.1101/2024.09.07.24313247
Oxidative stress markers predict treatment outcomes in patients with generalized anxiety disorder treated with selective serotonin reuptake inhibitors
No top-level findings curated for this source.
DOI:10.3390/ijms26115417
Molecular Basis of Anxiety: A Comprehensive Review of 2014–2024 Clinical and Preclinical Studies
No top-level findings curated for this source.
DOI:10.3390/nu16203564
Effect of Probiotics Supplementation on Cortisol Levels: A Systematic Review and Meta-Analysis
No top-level findings curated for this source.
DOI:10.3758/s13415-024-01162-3
Understanding the heterogeneity of anxiety using a translational neuroscience approach
No top-level findings curated for this source.
DOI:10.4236/psych.2023.141003
Generalized Anxiety Disorder: A Review of Current Literature in Saudi Arabia
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Generalized Anxiety Disorder
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 23

Key Pathophysiology Nodes

  • Amygdala Hyperactivity
  • GABA System Dysfunction
  • Serotonin Dysregulation
  • HPA Axis Dysregulation
  • Noradrenergic Hyperactivity
  • Oxidative Stress
  • Epigenetic Alterations
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1002/wps.21078
  • DOI:10.1038/s41380-023-02205-w
  • DOI:10.1038/s41588-024-01908-2
  • DOI:10.1038/s41598-025-90362-z
  • DOI:10.1101/2024.07.03.24309466
  • DOI:10.1101/2024.09.07.24313247
  • DOI:10.3390/ijms26115417
  • DOI:10.3390/nu16203564
  • DOI:10.3758/s13415-024-01162-3
  • DOI:10.4236/psych.2023.141003
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 23 citations 2025-12-17T23:35:46.213274

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Generalized Anxiety Disorder
  • MONDO ID: (if available)
  • Category: Complex

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Generalized Anxiety Disorder. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Disease Pathophysiology Research Template

Target Disease - Disease Name: Generalized Anxiety Disorder (GAD) - MONDO ID: MONDO_0001627 (Generalized anxiety disorder) - Category: Complex

Pathophysiology overview GAD arises from convergent dysfunction across inhibitory GABAergic signaling, monoaminergic (serotonergic/noradrenergic) modulation, stress-endocrine (HPA) axis regulation, glutamatergic plasticity, and immune–inflammatory pathways that remodel cortico-limbic threat circuits (amygdala–prefrontal cortex–hippocampus and bed nucleus of the stria terminalis, BNST). Large-scale multi-ancestry and European-ancestry GWAS map common-variant liability to dozens of loci enriched in brain-expressed genes and prioritize GABAergic mechanisms; EWAS and peripheral biomarker data point to stress-related epigenetic and oxidative signatures; imaging and electrophysiology indicate altered large-scale network connectivity and beta/gamma-band abnormalities. The gut–brain axis may modulate HPA signaling and systemic inflammation in anxiety. (friligkou2024genediscoveryand pages 1-3, strom2024genomewideassociationstudy pages 1-3, tomasi2024geneticinvestigationof pages 47-50, cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2)

1) Core pathophysiology - Inhibitory signaling deficits: GWAS meta-analyses identify 58 genome-wide variants and 66 supported genes for anxiety disorders, with follow-up analyses highlighting GABAergic signaling enrichment across major brain regions, consistent with impaired inhibitory control of threat circuits. This supports longstanding models of reduced GABA-A receptor–mediated inhibition within amygdala–PFC networks. URL: https://doi.org/10.1101/2024.07.03.24309466 (posted Jul 3, 2024). (strom2024genomewideassociationstudy pages 1-3) - Monoaminergic dysregulation: Reviews and candidate-gene syntheses implicate serotonergic transporters and receptors (SLC6A4/5-HTTLPR, HTR1A/HTR2A), norepinephrine/adrenergic genes, and dopaminergic regulators, aligning with SSRI/SNRI efficacy and noradrenergic arousal in anxiety. (tomasi2024geneticinvestigationof pages 47-50, merkouris2025molecularbasisof pages 1-2) - HPA-axis and cortisol: Chronic stress and impaired glucocorticoid feedback are repeatedly linked to anxiety pathophysiology; peripheral studies show elevated cortisol and blunted regulation in subsets; meta-analytic evidence indicates probiotics can modestly reduce cortisol, consistent with gut–brain modulation of HPA tone. URL (Nutrients meta-analysis Oct 2024): https://doi.org/10.3390/nu16203564. (merkouris2025molecularbasisof pages 1-2) - Glutamatergic plasticity: Converging reviews implicate glutamatergic signaling and synaptic plasticity (e.g., NTRK2/BDNF pathways from GWAS; circuit-level extinction learning under glucocorticoid modulation). (tomasi2024geneticinvestigationof pages 47-50, merkouris2025molecularbasisof pages 1-2) - Immune–inflammatory/oxidative stress: Clinical data in GAD demonstrate increased oxidative stress markers (elevated malondialdehyde/lipid hydroperoxides, reduced SOD/CAT/GSH-Px), which correlate with symptom severity and change with SSRI treatment; immune signaling and neuroinflammation are implicated as modulators of anxiety circuits. Preprint/early publication with URL: https://doi.org/10.1101/2024.09.07.24313247. (cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2)

2) Key molecular players - Genes/Proteins (HGNC): • GABA-A receptor subunits (e.g., GABRA1, GABRA2, GABRA3, GABRA5, GABRG1, GABRG3) prioritized via genetic enrichment and pharmacological relevance. (strom2024genomewideassociationstudy pages 1-3) • Serotonergic system: SLC6A4, HTR1A/HTR2A; noradrenergic: ADRA1A/ADRB2; dopaminergic: COMT/DAT1 (candidate synthesis). (tomasi2024geneticinvestigationof pages 47-50) • Neurotrophin signaling: NTRK2/BDNF implicated in GWAS/linkage and mechanistic models of plasticity. (tomasi2024geneticinvestigationof pages 47-50) • HPA-axis regulators: NR3C1 (GR), CRHR1; FKBP5 (candidate/epigenetic literature). (merkouris2025molecularbasisof pages 1-2, tomasi2024geneticinvestigationof pages 47-50) - Chemical entities (CHEBI): GABA, serotonin (5-HT), norepinephrine, cortisol; oxidative markers malondialdehyde (MDA), lipid hydroperoxides; antioxidants SOD, catalase, glutathione peroxidase. (cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2) - Cell types (CL): Cortical and amygdala parvalbumin-positive GABAergic interneurons (drivers of gamma oscillations) and principal glutamatergic pyramidal neurons; microglia as mediators of neuroinflammation. (merkouris2025molecularbasisof pages 1-2) - Anatomical locations (UBERON): Amygdala, hippocampus, medial/ventromedial/dorsomedial prefrontal cortex, anterior cingulate cortex, thalamus, BNST; large-scale networks include salience and default mode networks. (strom2024genomewideassociationstudy pages 1-3, merkouris2025molecularbasisof pages 1-2)

3) Biological processes (GO terms) - Synaptic signaling and inhibition: GABAergic synaptic transmission; regulation of membrane potential; inhibitory postsynaptic potential. (strom2024genomewideassociationstudy pages 1-3) - Monoaminergic neurotransmission: serotonin transport and receptor signaling; adrenergic receptor signaling. (tomasi2024geneticinvestigationof pages 47-50) - Stress response: response to glucocorticoid; regulation of HPA axis; response to cortisol; fear learning and extinction. (merkouris2025molecularbasisof pages 1-2) - Neuroinflammation/immune signaling: microglial activation; cytokine-mediated signaling pathway; oxidative stress response; cellular response to reactive oxygen species. (cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2) - Synaptic plasticity: long-term potentiation/depression; neurotrophin/TrkB signaling. (tomasi2024geneticinvestigationof pages 47-50)

4) Cellular components (GO-CC) - GABA-A receptor complex at inhibitory synapse; postsynaptic density; presynaptic active zone. - Glucocorticoid receptor complex (cytosol/nucleus); mitochondrial membrane (oxidative stress sites). - Extracellular space/plasma and saliva (peripheral cortisol and inflammatory markers). (cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2)

5) Disease progression (conceptual sequence) - Predisposition: Polygenic risk distributed across 51–58 loci (multi-ancestry and European GWAS) enriched in brain-expressed genes, with notable GABAergic involvement. URL Nature Genetics (Sep 2024): https://doi.org/10.1038/s41588-024-01908-2; medRxiv (Jul 2024): https://doi.org/10.1101/2024.07.03.24309466. (friligkou2024genediscoveryand pages 1-3, strom2024genomewideassociationstudy pages 1-3) - Environmental inputs: Early-life stress and chronic psychosocial stress engage HPA, induce epigenetic changes (e.g., NR3C1 methylation), and promote inflammatory/oxidative states. (merkouris2025molecularbasisof pages 1-2) - Circuit remodeling: Reduced inhibitory control (GABAergic interneuron dysfunction) and altered monoaminergic gain destabilize amygdala–PFC–hippocampal/BST circuits, biasing threat appraisal and sustained anxiety; network-level dysconnectivity emerges. (strom2024genomewideassociationstudy pages 1-3, merkouris2025molecularbasisof pages 1-2) - Clinical manifestation: Persistent, excessive worry, hyperarousal, and somatic symptoms; peripheral biomarkers show elevated oxidative stress and sometimes altered cortisol. (cui2025oxidativestressmarkers pages 11-13, bamalan2023generalizedanxietydisorder pages 3-6)

6) Phenotypic manifestations (HP terms) - Excessive worry and anxiety (HP:0000739), restlessness (HP:0000711), sleep disturbance/insomnia (HP:0100785), concentration impairment (HP:0100543), autonomic hyperarousal (e.g., palpitations HP:0001962, sweating HP:0000975), muscle tension (HP:0001371). (bamalan2023generalizedanxietydisorder pages 3-6)

Recent developments (2023–2024 priority) - Multi-ancestry GWAS in Nature Genetics (Sep 2024): Identified 51 loci (39 novel), with heritability enrichment in limbic system, cortex, cerebellum; cross-ancestry PRS transferability; 115 transcriptome/proteome-nominated genes, mapping risk to brain systems implicated in anxiety. URL: https://doi.org/10.1038/s41588-024-01908-2. (friligkou2024genediscoveryand pages 1-3) - European mega-GWAS (Jul 2024): 58 independent loci, 66 genes, replicated 51/58 in 1.17M cases; pathway enrichment highlights GABAergic signaling; broad brain enrichment supports systems-level liability. URL: https://doi.org/10.1101/2024.07.03.24309466. (strom2024genomewideassociationstudy pages 1-3) - EWAS of anxiety disorders (Aug 2023): Methylome-wide analysis across anxiety phenotypes demonstrates DNAm associations, supporting stress-related epigenetic involvement in anxiety biology. URL: https://doi.org/10.1038/s41380-023-02205-w. (tomasi2024geneticinvestigationof pages 47-50) - Biomarkers and electrophysiology/imaging updates: • EEG in GAD (Scientific Reports 2025): Increased beta power and reduced fronto-temporal and fronto-parietal/occipital connectivity, plus rightward temporal alpha asymmetry, provide candidate electrophysiological markers of altered excitatory–inhibitory balance and network integration. URL: https://doi.org/10.1038/s41598-025-90362-z. (merkouris2025molecularbasisof pages 1-2) • World Psychiatry 2023 biomarker state-of-field review: Identifies error-related negativity (ERN) as a promising predictive biomarker for first-onset GAD, while overall emphasizing the lack of clinically validated markers and the need for rigorous validation. URL: https://doi.org/10.1002/wps.21078 (May 2023). (merkouris2025molecularbasisof pages 1-2) • Probiotics and cortisol (Nutrients 2024 meta-analysis): Across 46 RCTs (n=3516), probiotics modestly reduce cortisol (SMD −0.45; low certainty), consistent with gut–brain–HPA modulation but underscoring heterogeneity. URL: https://doi.org/10.3390/nu16203564 (Oct 2024). (merkouris2025molecularbasisof pages 1-2) - Oxidative stress in GAD and treatment response (2024/2025): Elevated baseline MDA/LPO and reduced antioxidant enzymes correlate with symptom severity; changes track SSRI response with ROC AUC ~0.80 for baseline MDA predicting response. URL: https://doi.org/10.1101/2024.09.07.24313247. (cui2025oxidativestressmarkers pages 11-13)

Circuits, networks, and cell types - Threat and sustained anxiety circuitry: Dysregulation in amygdala–mPFC–hippocampus and BNST underpins exaggerated threat appraisal and persistent anxiety; genetic enrichment across broad brain regions supports network-level liability. (strom2024genomewideassociationstudy pages 1-3, friligkou2024genediscoveryand pages 1-3) - Large-scale networks: Altered connectivity within salience and default-mode networks is consistent with hypervigilance and perseverative cognition. Multicenter rs-fMRI in anxiety disorders reports insula–thalamus increases and midbrain–cortical dysconnectivity, with disorder-specific patterns; these findings align with GAD literature on cortico-limbic dysconnectivity. (merkouris2025molecularbasisof pages 1-2) - Cell types: PV+ GABA interneuron dysfunction is a cross-disorder model for gamma-band changes; microglial activation and neuroinflammation are implicated via TSPO literature and preclinical anxiolytics modulating neurosteroids/microglia. (merkouris2025molecularbasisof pages 1-2)

Applications and real-world implementations - Genetic risk and target nomination: The 2024 GWASs provide prioritized genes and pathways for functional follow-up (e.g., GABA-A receptor subunits) and potential stratification in clinical trials. (strom2024genomewideassociationstudy pages 1-3, friligkou2024genediscoveryand pages 1-3) - Biomarker development: ERN for GAD risk prediction; EEG beta/gamma and connectivity metrics as candidate markers; however, current consensus emphasizes limited clinical readiness and the need for validation pipelines. (merkouris2025molecularbasisof pages 1-2) - Adjunctive strategies: Gut–brain axis modulation (diet/probiotics) may modestly influence HPA and symptomatology; peripheral oxidative stress panels (e.g., MDA, antioxidant enzymes) show promise for monitoring and response prediction but require replication. (cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2)

Expert opinions and authoritative analyses - World Psychiatry consensus (2023) stresses the gap between numerous candidate biomarkers and a paucity of clinically validated tools; prioritizes definitive testing of a limited set (e.g., ERN for GAD onset prediction). URL: https://doi.org/10.1002/wps.21078. (merkouris2025molecularbasisof pages 1-2) - Translational reviews highlight heterogeneity and advocate cross-species and computational models to bridge mechanisms and clinical phenotypes in anxiety. URL: https://doi.org/10.3758/s13415-024-01162-3 (Feb 2024). (merkouris2025molecularbasisof pages 1-2)

Relevant statistics and data - Common-variant risk: 51 loci identified (39 novel) in multi-ancestry GWAS (Nature Genetics 2024) and 58 loci in European mega-GWAS (medRxiv 2024), with replication of 51/58 variants in an independent 1.17M-case dataset; enrichment in GABAergic signaling and brain-wide expression. (friligkou2024genediscoveryand pages 1-3, strom2024genomewideassociationstudy pages 1-3) - Epigenetics: Methylome-wide associations observed for anxiety disorders (Molecular Psychiatry 2023), supporting systemic stress-related DNAm signatures; specific CpGs vary across cohorts. (tomasi2024geneticinvestigationof pages 47-50) - Electrophysiology: In GAD, increased beta activity and decreased long-range connectivity (fronto–temporal/parietal/occipital), plus rightward alpha asymmetry, suggesting altered E/I balance and network integration. (merkouris2025molecularbasisof pages 1-2) - Oxidative stress: Baseline serum MDA ROC AUC ~0.80 for SSRI response; group differences and correlations with severity reported (details above). (cui2025oxidativestressmarkers pages 11-13) - Gut–brain/HPA: Probiotics meta-analysis shows cortisol reduction SMD −0.45 (low certainty) across 46 RCTs. (merkouris2025molecularbasisof pages 1-2)

Ontology-style annotations (examples) - Genes/Proteins (HGNC): GABRA1, GABRA2, GABRA3, GABRA5, GABRG1, GABRG3; SLC6A4; HTR1A; HTR2A; NTRK2; BDNF; NR3C1; CRHR1; FKBP5. (strom2024genomewideassociationstudy pages 1-3, tomasi2024geneticinvestigationof pages 47-50, merkouris2025molecularbasisof pages 1-2) - Biological processes (GO): GABAergic synaptic transmission; serotonergic signaling pathway; adrenergic receptor signaling; response to glucocorticoid; regulation of synaptic plasticity; microglial activation; response to oxidative stress. (strom2024genomewideassociationstudy pages 1-3, tomasi2024geneticinvestigationof pages 47-50, cui2025oxidativestressmarkers pages 11-13) - Cellular components (GO-CC): GABA-A receptor complex; postsynaptic density; cytosol/nuclear GR complex; mitochondrial membrane. (strom2024genomewideassociationstudy pages 1-3, cui2025oxidativestressmarkers pages 11-13) - Cell types (CL): Parvalbumin-expressing GABAergic interneuron; glutamatergic pyramidal neuron; microglial cell. (merkouris2025molecularbasisof pages 1-2) - Anatomical (UBERON): Amygdala (UBERON:0001872), hippocampus (UBERON:0001954), prefrontal cortex (UBERON:0001870), anterior cingulate cortex (UBERON:0001873), thalamus (UBERON:0001897), BNST (UBERON:0001882). (strom2024genomewideassociationstudy pages 1-3, friligkou2024genediscoveryand pages 1-3) - Chemical entities (CHEBI): gamma-aminobutyric acid; serotonin; norepinephrine; cortisol; malondialdehyde. (cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2) - Phenotypes (HP): Anxiety (HP:0000739), Insomnia (HP:0100785), Palpitations (HP:0001962), Sweating (HP:0000975), Muscle hypotonia/tension as applicable. (bamalan2023generalizedanxietydisorder pages 3-6)

Evidence items with links - Friligkou et al., Nature Genetics, Sep 2024: https://doi.org/10.1038/s41588-024-01908-2. Multi-ancestry GWAS; 51 loci; limbic/cortical enrichment; PRS transferability. (friligkou2024genediscoveryand pages 1-3) - Strom et al., medRxiv, Jul 2024: https://doi.org/10.1101/2024.07.03.24309466. European mega-GWAS; 58 loci; GABAergic enrichment; 51/58 replicated. (strom2024genomewideassociationstudy pages 1-3) - Hettema et al., Molecular Psychiatry, Aug 2023: https://doi.org/10.1038/s41380-023-02205-w. Methylome-wide association in anxiety disorders. (tomasi2024geneticinvestigationof pages 47-50) - Abi-Dargham et al., World Psychiatry, May 2023: https://doi.org/10.1002/wps.21078. Biomarker state-of-field; ERN identified for GAD onset prediction. (merkouris2025molecularbasisof pages 1-2) - Jain et al., Nutrients, Oct 2024: https://doi.org/10.3390/nu16203564. Probiotics meta-analysis: cortisol reduction (SMD −0.45). (merkouris2025molecularbasisof pages 1-2) - Cui et al., medRxiv/Neuropsychobiology 2025: https://doi.org/10.1101/2024.09.07.24313247. Oxidative stress markers in GAD; treatment response prediction AUC ~0.80. (cui2025oxidativestressmarkers pages 11-13)

Limitations and open questions - Heterogeneity across anxiety phenotypes and comorbidities complicates disorder-specific inference; many biomarkers remain preclinical or unvalidated clinically. (merkouris2025molecularbasisof pages 1-2) - EWAS signals require replication and tissue-specific mechanistic mapping; directionality of cortisol alterations varies with context and sampling.

Conclusion Current evidence places GAD within a polygenic, circuit-level disorder of inhibitory control, monoaminergic modulation, and stress endocrine regulation, with immune–oxidative processes and gut–brain interactions as modulators. Genetic findings newly prioritize GABAergic signaling; electrophysiological and imaging markers reflect altered network dynamics; peripheral oxidative and endocrine signatures show potential for monitoring. Continued multi-omic, longitudinal, and mechanistic studies are needed to translate these convergences into validated biomarkers and precision therapeutics. (friligkou2024genediscoveryand pages 1-3, strom2024genomewideassociationstudy pages 1-3, tomasi2024geneticinvestigationof pages 47-50, cui2025oxidativestressmarkers pages 11-13, merkouris2025molecularbasisof pages 1-2)

References

  1. (friligkou2024genediscoveryand pages 1-3): Eleni Friligkou, Solveig Løkhammer, Brenda Cabrera-Mendoza, Jie Shen, Jun He, Giovanni Deiana, Mihaela Diana Zanoaga, Zeynep Asgel, Abigail Pilcher, Luciana Di Lascio, Ana Makharashvili, Dora Koller, Daniel S. Tylee, Gita A. Pathak, and Renato Polimanti. Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study. Nature genetics, 56:2036-2045, Sep 2024. URL: https://doi.org/10.1038/s41588-024-01908-2, doi:10.1038/s41588-024-01908-2. This article has 50 citations and is from a highest quality peer-reviewed journal.

  2. (strom2024genomewideassociationstudy pages 1-3): Nora I. Strom, Brad Verhulst, Silviu-Alin Bacanu, Rosa Cheesman, Kirstin L. Purves, Hüseyin Gedik, Brittany L. Mitchell, Alex S. Kwong, Annika B. Faucon, Kritika Singh, Sarah Medland, Lucia Colodro-Conde, Kristi Krebs, Per Hoffmann, Stefan Herms, Jan Gehlen, Stephan Ripke, Swapnil Awasthi, Teemu Palviainen, Elisa M. Tasanko, Roseann E. Peterson, Daniel E. Adkins, Andrey A. Shabalin, Mark J. Adams, Matthew H. Iveson, Archie Campbell, Laurent F. Thomas, Bendik S. Winsvold, Ole Kristian Drange, Sigrid Børte, Abigail R. ter Kuile, Tan-Hoang Nguyen, Sandra M. Meier, Elizabeth C. Corfield, Laurie Hannigan, Daniel F. Levey, Darina Czamara, Heike Weber, Karmel W. Choi, Giorgio Pistis, Baptiste Couvy-Duchesne, Sandra Van der Auwera, Alexander Teumer, Robert Karlsson, Miguel Garcia-Argibay, Donghyung Lee, Rujia Wang, Ottar Bjerkeset, Eystein Stordal, Julia Bäckmann, Giovanni A. Salum, Clement C. Zai, James L. Kennedy, Gwyneth Zai, Arun K. Tiwari, Stefanie Heilmann-Heimbach, Börge Schmidt, Jaakko Kaprio, Martin M. Kennedy, Joseph Boden, Alexandra Havdahl, Christel M. Middeldorp, Fabiana L. Lopes, Nirmala Akula, Francis J. McMahon, Elisabeth B. Binder, Lydia Fehm, Andreas Ströhle, Enrique Castelao, Henning Tiemeier, Dan J. Stein, David Whiteman, Catherine Olsen, Zachary Fuller, Xin Wang, Naomi R. Wray, Enda M. Byrne, Glyn Lewis, Nicholas J. Timpson, Lea K. Davis, Ian B. Hickie, Nathan A. Gillespie, Lili Milani, Johannes Schumacher, David P. Woldbye, Andreas J. Forstner, Markus M. Nöthen, Iiris Hovatta, John Horwood, William E. Copeland, Hermine H. Maes, Andrew M. McIntosh, Ole A. Andreassen, John-Anker Zwart, Ole Mors, Anders D. Børglum, Preben B. Mortensen, Helga Ask, Ted Reichborn-Kjennerud, Jackob M. Najman, Murray B. Stein, Joel Gelernter, Yuri Milaneschi, Brenda W. Penninx, Dorret I. Boomsma, Eduard Maron, Angelika Erhardt-Lehmann, Christian Rück, Tilo T. Kircher, Christiane A. Melzig, Georg W. Alpers, Volker Arolt, Katharina Domschke, Jordan W. Smoller, Martin Preisig, Nicholas G. Martin, Michelle K. Lupton, Annemarie I. Luik, Andreas Reif, Hans J. Grabe, Henrik Larsson, Patrik K. Magnusson, Albertine J. Oldehinkel, Catharina A. Hartman, Gerome Breen, Anna R. Docherty, Hilary Coon, Rupert Conrad, Kelli Lehto, Jürgen Deckert, Thalia C. Eley, Manuel Mattheisen, and John M. Hettema. Genome-wide association study of major anxiety disorders in 122,341 european-ancestry cases identifies 58 loci and highlights gabaergic signaling. MedRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.03.24309466, doi:10.1101/2024.07.03.24309466. This article has 19 citations.

  3. (tomasi2024geneticinvestigationof pages 47-50): J Tomasi. Genetic investigation of physiological phenotypes to understand anxiety mechanisms. Unknown journal, 2024.

  4. (cui2025oxidativestressmarkers pages 11-13): Lijun Cui, Jingjing Lu, Zhongxia Shen, Jielin Zhu, Huanxin Chen, Shenliang Yang, Shikai Wang, and Xinhua Shen. Oxidative stress markers predict treatment outcomes in patients with generalized anxiety disorder treated with selective serotonin reuptake inhibitors. Neuropsychobiology, pages 1-19, Sep 2025. URL: https://doi.org/10.1101/2024.09.07.24313247, doi:10.1101/2024.09.07.24313247. This article has 3 citations and is from a peer-reviewed journal.

  5. (merkouris2025molecularbasisof pages 1-2): Ermis Merkouris, Alexandra Brasinika, Meropi Patsiavoura, Chrysanthi Siniosoglou, Dimitrios Tsiptsios, Andreas S. Triantafyllis, Christoph Mueller, Ioulia Mpikou, Myrto T. Samara, Nikolaos Christodoulou, and Konstantinos Tsamakis. Molecular basis of anxiety: a comprehensive review of 2014–2024 clinical and preclinical studies. International Journal of Molecular Sciences, 26:5417, Jun 2025. URL: https://doi.org/10.3390/ijms26115417, doi:10.3390/ijms26115417. This article has 2 citations and is from a poor quality or predatory journal.

  6. (bamalan2023generalizedanxietydisorder pages 3-6): Omar Abdulqader Bamalan, Nader Mohammed Alosaimi, Abdulrahman Abdulrazzaq Alfryyan, Hussain Jawad Aljubran, Faris Hamoud Alanazi, and Zaheenul Islam Siddiqui. Generalized anxiety disorder: a review of current literature in saudi arabia. Psychology, 14:35-51, Jan 2023. URL: https://doi.org/10.4236/psych.2023.141003, doi:10.4236/psych.2023.141003. This article has 8 citations and is from a poor quality or predatory journal.